Merck & Co Announce Increased Profit for Q1

Merck & Co’s have released their Q1 results for 2014, showing an increase in profit, despite being hindered by unfavourable exchange rates and patents expiring. The healthcare company announced net income of $1.70 billion, an increase from the $1.59 billion net income of Merck & Co’s first quarter of 2013.  However, turnover for the business

Continue Reading

Abbott Announces 2014 Q1 Results

Abbott yesterday revealed financial results for the first quarter of 2014.  The company announced worldwide sales of $5.2 billion. Excluding foreign exchange, the company-wide results included an increase of 0.5% on an operational basis and a decrease of 2.5% on a reported basis. International sales, which make up over 70% of Abbott’s total sales, increased

Continue Reading

Meda Rejects Mylan Takeover Bid

Swedish drugmaker, Meda, have confirmed that they have rejected a takeover bid from US generics major, Mylan. Shares in Meda, which markets specialty treatments, over-the-counter products and branded generics, were frozen after a report from the Financial Times noted that Mylan was planning to submit an offer that would create a $23 billion company.  The Financial Times cited someone

Continue Reading

Celgene Partners with Abide Therapeutics

Abide Therapeutics and Celgene have announced that they will be collaborating to discover and develop drugs in inflammation and immunology. As part of the terms of the partnership, Celgene has paid an upfront fee, reported to be $50 million, and will obtain a small equity stake in Abide Therapeutics.  The deal also provides Celgene with

Continue Reading

Novartis Announces Closure of Horsham Site

Novartis yesterday confirmed that they will be closing all operations at their Horsham site later this year, putting nearly 400 jobs at risk. The Swiss pharmaceutical organisation initially announced in November that they were considering the site’s closure as part of their global review of R&D locations.  Following from the announcement, Novartis has now confirmed

Continue Reading

AbbVie Reports Drop in Sales

Generic competition and foreign exchange rate has resulted in AbbVie reporting a drop in fourth-quarter sales, however their anti-inflammatory blockbuster Humira continues to soar. The company announced a net income of $1.13 billion, down 27%, while fourth quarter revenues dropped slightly to $5.11 billion. The majority of AbbVie’s revenue was gained from Humira (adalimumab), which

Continue Reading